Who's Hired? Padagis Gets New Leadership
As Celltrion Appoints A CCO In The US And Biosimilars Canada Elects Fresh Chair
Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.
You may also be interested in...
Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Celltrion is taking a major step forward in the US with its first direct launch of a biosimilar through its own front-end operation. The Korean firm’s Vegzelma rival to Avastin will be looking to compete with multiple other versions of bevacizumab already in the market.